FDA bats back AstraZeneca's SGLT diabetes drug for Type 1 diabetes — blocking a class on safety fears
The FDA has just fired its latest salvo at the SGLT class of diabetes drugs, blowing up some commercial opportunity at AstraZeneca as part of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
